Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS

Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need Neridronic acid is the first investigational med... Biopharmaceuticals, FDA Grünenthal, Abiogen Pharma, neridronic acid, CRPS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news